Telcoin Makes U.S. Banking History with Approval to Launch the First Regulated Digital Asset Bank
Telcoin today announced its final charter approval from the Nebraska Department of Banking and Finance to launch Telcoin Digital Asset Bank, the first Digital Asset Depository Institution in the United States. The charter positions Telcoin to become the first true blockchain bank, directly connecting U.S. bank accounts to regulated “Digital Cash” stablecoins. Its flagship product, eUSD, will be the first bank-issued, on-chain U.S. dollar stablecoin, offering consumers and businesses a secure, compliant way to use Digital Cash for payments, remittances, and savings. Notably, it is also the first bank charter to explicitly authorize connecting U.S. consumers to DeFi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112119122/en/
Telcoin’s eUSD and other global Digital Cash stablecoins represent an evolution of money that is programmable and interoperable, designed to move seamlessly across blockchain and traditional financial rails. Unlike unregulated, offshore, or non-bank stablecoins, eUSD is fully backed by U.S. dollar deposits and short-term Treasuries held in regulated reserves. Telcoin believes that the trust that comes with being regulated as a bank will drive consumer adoption as well as the institutional adoption needed to scale blockchain-powered finance to the broader market.
“Our charter makes history, and not just for Telcoin, but for the entire U.S. banking system,” said Paul Neuner, Telcoin’s Founder and CEO. “We’re proving that a bank can issue on-chain Digital Cash responsibly and operate in full alignment with U.S. regulators. eUSD brings the speed, transparency, and affordability of blockchain into everyday finance in a way that anyone can use.”
The approval coincides with the recent passage of the GENIUS Act, which provides long-awaited federal guidance for stablecoins and digital assets. While blockchain industry peers are seeking to operate as non-depository trust charters, Telcoin is providing a solution to the systemic risk concerns around stablecoins expressed by federal regulators.
“For us, this is not about stablecoins pulling money out of the banking system, but rather upgrading the technology of money, payments, and banking itself,” Neuner explains, adding that the bank’s native medium of transaction is a regulated, on-chain digital dollar directly connected to U.S. account numbers. More than just a stablecoin issuer, the bank plans to provide compliant stablecoin yield offerings along with a suite of retail and commercial depository services, subject to regulatory approval.
Telcoin Digital Asset Bank also intends to help community banks nationwide adapt to the evolving technology. “There are almost 5,000 banks in the U.S., and only the largest five percent of them will be able to do digital assets in-house,” said Patrick Gerhart, President of Banking Operations at Telcoin. “We look forward to helping the other 95 percent of U.S. banks stay relevant and connect to blockchain-based finance in a safe and sound manner.”
By aligning digital assets within a regulated banking framework, Telcoin Digital Asset Bank bridges the $4 trillion blockchain economy with traditional finance to unlock this technology for modern money, capital markets, and finance on the internet. This model demonstrates how Digital Cash can strengthen community bank balance sheets, empower small businesses, and modernize payments at scale, setting a new standard for how blockchain and banking can work together.
“We’ve been working toward this landmark for years, and now Telcoin Digital Asset Bank gets to serve as a prime example for how both compliance and innovation can work together to elevate the standard of banking,” adds Neuner. “On a global stage, Telcoin will demonstrate how local institutions, national regulators, and international innovators can move together to make money flow at the speed of the internet.”
Governor Jim Pillen signed the charter at the Nebraska State Capitol in Lincoln today, where the Nebraska Financial Innovation Act became law in 2021. That initiative, spearheaded by former Nebraska Speaker and current U.S. Congressman Mike Flood, laid the foundation for today’s charter issuance. Nebraska Department of Banking and Finance Director Kelly Lammers was also instrumental in developing the Digital Asset Depository Institution charter from the NFIA, placing Nebraska at the center of the national landscape for blockchain banking innovation.
ABOUT TELCOIN
Telcoin, a multinational fintech serving 171 countries, is revolutionizing global finance by merging blockchain technology, telecommunications, and banking. Telcoin Digital Asset Bank is a Digital Asset Depository Institution in establishment under charter from the Nebraska Department of Banking and Finance. It will issue eUSD, the first regulated, bank-issued U.S. dollar stablecoin. Telcoin offers secure, self-custodial blockchain payments and banking services globally, powered by its own decentralized financial infrastructure. This compliant, banking-first approach harnesses blockchain's power to redefine how the world interacts with money on the internet. Learn more at www.telco.in.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112119122/en/
Contacts
MEDIA CONTACT
Janelle Burdette Redden
janelle@scrib3.co
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom